Market closedNon-fractional
Fulcrum Therapeutics/FULC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Fulcrum Therapeutics
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Ticker
FULC
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Cambridge, United States
Employees
76
Website
www.fulcrumtx.com
FULC Metrics
BasicAdvanced
$537M
Market cap
-
P/E ratio
-$1.61
EPS
2.33
Beta
-
Dividend rate
Price and volume
Market cap
$537M
Beta
2.33
Financial strength
Current ratio
20.381
Quick ratio
20.048
Long term debt to equity
3.795
Total debt to equity
4.746
Management effectiveness
Return on assets (TTM)
-25.41%
Return on equity (TTM)
-39.00%
Valuation
Price to revenue (TTM)
212.991
Price to book
2.52
Price to tangible book (TTM)
2.52
Price to free cash flow (TTM)
-5.78
Growth
Revenue change (TTM)
-37.95%
Earnings per share change (TTM)
-26.46%
3-year revenue growth (CAGR)
-42.00%
3-year earnings per share growth (CAGR)
-13.90%
What the Analysts think about FULC
Analyst Ratings
Majority rating from 9 analysts.
FULC Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-100.00%
Net income
-$27M
8.50%
Profit margin
0.00%
-100.00%
FULC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.38
-$0.39
-$0.40
-$0.43
-
Expected
-$0.44
-$0.44
-$0.43
-$0.44
-$0.01
Surprise
-14.52%
-10.34%
-6.04%
-1.71%
-
FULC News
AllArticlesVideos
Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
GlobeNewsWire·3 days ago
Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter
Benzinga·1 week ago
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Fulcrum Therapeutics stock?
Fulcrum Therapeutics (FULC) has a market cap of $537M as of July 27, 2024.
What is the P/E ratio for Fulcrum Therapeutics stock?
The price to earnings (P/E) ratio for Fulcrum Therapeutics (FULC) stock is 0 as of July 27, 2024.
Does Fulcrum Therapeutics stock pay dividends?
No, Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Fulcrum Therapeutics dividend payment date?
Fulcrum Therapeutics (FULC) stock does not pay dividends to its shareholders.
What is the beta indicator for Fulcrum Therapeutics?
Fulcrum Therapeutics (FULC) has a beta rating of 2.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Fulcrum Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.